Company Mission & Profile

22nd Century is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.

Our proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our very low nicotine (VLN) tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.

Protecting our technology are more than 200 issued patents and more than 50 pending patent applications around the world.

Goodrich Tobacco Company, LLC, Botanical Genetics, NASCO Products, LLC, and Heracles Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century Group.

2015 Annual Report


Download 2015 Annual Report (PDF)

XXII Stock Quote


Advisory note: global nicotine reduction strategy

WHO Study Group on Tobacco Product Regulation


This advisory note presents the conclusions and recommendations of the members of the WHO Study Group on Tobacco Product Regulation (TobReg) on a policy for limiting the sale of cigarettes to brands with a nicotine content that is not sufficient to lead to the development and/or maintenance of addiction.

SOURCE: WHO Global Nicotine Reduction Strategy


Landmark Study on Very Low Nicotine Cigarettes

Randomized Trial of Reduced-Nicotine Standards for Cigarettes
– Eric C. Donny, Ph.D., et. al.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes (Key Points Video)

Reduced-Nicotine Cigarettes — A Promising Regulatory Pathway
– Michael Fiore, M.D., M.P.H., M.B.A., and Timothy Baker, Ph.D.